← Back to Search

Targeted Therapy

Experimental Group for Pancreatic Cancer

Phase 1 & 2

Waitlist Available

Led By Devalingam Mahalingam, MD

Research Sponsored by Devalingam Mahalingam

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Approved for 10 Other Conditions

All Individual Drugs Already Approved

No Placebo-Only Group

Summary

This trial will test a new cancer drug, sotorasib, to see if it is safe and effective when combined with standard chemotherapy for treating pancreatic cancer that has progressed after first-line treatment.

Eligible Conditions

Pancreatic Cancer
KRAS Mutation

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Objective Response Rate (ORR)

Secondary study objectives

Assess Adverse Events

Disease Control Rate (DCR)

Duration of Response (DoR)

+2 more

Awards & Highlights

Approved for 10 Other Conditions

This treatment demonstrated efficacy for 10 other conditions.

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Experimental GroupExperimental Treatment6 Interventions

Patients will either receive a combination of: Sotorasib + Liposomal Irinotecan (nal-IRI) + 5 Fluorouracil (5FU) + Leucovorin (LV) OR Sotorasib + Gemcitabine (GEM) + Nab-paclitaxel \*The combination of therapy received is based on the participants prior therapy and of the discretion of their treating physician

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Sotorasib

FDA approved

Paclitaxel

FDA approved

Leucovorin

FDA approved

Do I qualify?Apply below to find out